Substance / Medication

Doxazosin mesylate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

4 trials linked to this intervention

4
Total Trials
1
Recruiting
2
With Results

Research Evidence

Published studies and systematic reviews

Sort:
[Treatment of Benign Prostatic Hyperplasia by Longbishu Capsule Combined Doxazosin Mesylate Tablet].
Song Chun-Sheng, Zhao Jia-You, Guo Jun et al. · Zhongguo Zhong Xi Yi Jie He Za Zhi · 2016
PMID: 30650291RCT
LC-MS determination and relative bioavailability of doxazosin mesylate tablets in healthy Chinese male volunteers.
Ma Ning, Liu Wenying, Li Huande et al. · J Pharm Biomed Anal · 2007
PMID: 17055685RCT
Effects of doxazosin mesylate versus nifedipine on blood pressure variability in hypertensive patients: a randomized crossover study (SIMILAR).
Shi Jing, Liang Desen, Pan Yujiao et al. · Blood Press Monit · 2019
PMID: 31116151Observational
Effects of the chronic use of finasteride and doxazosin mesylate on the histomorphometric characteristics of the prostate: experimental study in rats.
Fornari Alexandre, Rhoden Ernani Luis, Zettler Cláudio G et al. · Int Urol Nephrol · 2011
PMID: 20532625Observational
Enantiomeric resolution of doxazosin mesylate and its process-related substances on polysaccharide chiral stationary phases.
Nageswara Rao R, Nagaraju D, Narasa Raju A · J Pharm Biomed Anal · 2006
PMID: 16495033Observational
Sex-specific formulations of doxazosin mesylate via direct powder extrusion 3D printing.
Januskaite Patricija, Goyanes Alvaro, Orlu Mine et al. · Drug Deliv Transl Res · 2025
PMID: 40263229OtherFull text (PMC)
Sustained release microneedle patch for pronounced systemic delivery of doxazosin mesylate.
Anwar Imran, Zafar Nadiah, Mahmood Asif et al. · Bioimpacts · 2025
PMID: 40161943OtherFull text (PMC)
Oral bioavailability enhancement of doxazosin mesylate: Nanosuspension versus self-nanoemulsifying drug delivery systems.
Al Ashmawy Al Zahraa G, Alyami Mohammad H, Eissa Noura G et al. · ADMET DMPK · 2024
PMID: 38560714OtherFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Doxazosin mesilate (substance)
SNOMED CT
108557002
UMLS CUI
C0077770

Clinical Data

This intervention maps to 8 entities in the Healos knowledge graph.

4
Conditions
1
Biomarkers
2
Specialists
0
Symptoms
4
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.